Spinning Out mGluRs

Merck Serono spins out Prexton to develop mGluR assets for Parkinson's

Although Merck Serono S.A. decided to drop Parkinson's disease from its neuroscience portfolio, its preclinical compounds targeting metabotropic glutamate receptors for PD will continue to live on in a newco called Prexton Therapeutics S.A.

Backed by Merck Serono's newly established spinout fund, Prexton hopes to generate proof-of-principle data for the molecules over the next year to attract external venture investors for a series A round.

The pharma, a unit of Merck KGaA, announced in February that it would restructure, a move that included a decision to focus its neuroscience

Read the full 872 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE